The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
CD19‐directed chimeric antigen receptor T lymphocytes (CAR‐T) have led to durable remissions in children with refractory and/or multiply relapsed B‐lymphoblastic leukemia. For those who relapse or lose B‐cell aplasia post CAR‐T, the role of CAR‐T reinfusion is unclear. We report two cases of durable remission with tisagenlecleucel reinfusion despite failure to achieve or maintain B‐cell aplasia, and...
Chimeric antigen receptor T cells (CAR‐T) are an effective and potentially durable treatment for refractory and multiply relapsed B‐cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR‐T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life‐threatening. Providers have exercised caution in providing...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.